Double-Drug attack targets tough lung cancer

NCT ID NCT07655622

Recruiting now Disease control Sponsor: Second Affiliated Hospital of Nanchang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial investigates whether combining two targeted drugs, vebreltinib and furmonertinib, can control advanced non-small cell lung cancer in people whose tumors have both an EGFR mutation and high PD-L1 expression. The study enrolls about 45 adults who have not received prior treatment for advanced disease. Researchers will monitor how long the cancer stays under control and track any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vebreltinib and furmonertinib
What this could lead to: If successful, this drug combination could offer a new first-line treatment option for people with a specific type of advanced lung cancer.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. Side effects from combining two targeted therapies are not yet fully known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

The Second Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jianxi, 330006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.